Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.53 |
| ▸ | JAK2 | O60674 | 6/20 | 0.35 |
| ▸ | JAK1 | P23458 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1056466 | 0.87 | GPR119 (0.55) | GPR119 | |
| SCHEMBL1061146 | 0.87 | GPR119 (0.57) | GPR119 | |
| SCHEMBL1060144 | 0.86 | GPR119 (0.73) | GPR119 | |
| SCHEMBL2634581 | 0.85 | GPR119 (0.58) | GPR119JAK2KMT2A | |
| SCHEMBL8511959 | 0.82 | GPR119 (0.76) | GPR119JAK2JAK1 | |
| SCHEMBL1060870 | 0.80 | GPR119 (0.61) | GPR119JAK2JAK1KMT2A | |
| SCHEMBL8515380 | 0.79 | GPR119 (0.60) | GPR119JAK2JAK1KMT2A | |
| SCHEMBL8515560 | 0.78 | GPR119 (0.57) | GPR119KMT2ARAB9A | |
| SCHEMBL1061706 | 0.78 | GPR119 (0.44) | GPR119JAK2JAK1KMT2ARAB9A | |
| SCHEMBL2634983 | 0.78 | GPR119 (0.60) | GPR119JAK2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2643310-A1 | 4- (5-CYANO-PYRAZOL-1-YL) -PIPERIDINE DERIVATIVES AS GPR 119 MODULATORS | Pfizer Inc (US) | 2013-10-02 | — | — | EP | disclosed |
| WO-2012069948-A1 | 4- (5-CYANO-PYRAZOL-1-YL) -PIPERIDINE DERIVATIVES AS GPR 119 MODULATORS | PFIZER INC. (US) | 2012-05-31 | — | — | WO | disclosed |
| EP-2438051-A1 | L- ( PIPERIDIN-4-YL) -PYRAZOLE DERIVATIVES AS GPR 119 MODULATORS | Pfizer Inc. (US) | 2012-04-11 | — | — | EP | disclosed |
| US-20110020460-A1 | GPR 119 MODULATORS | PFIZER INC. | 2011-01-27 | — | — | US | disclosed |
| WO-2010140092-A1 | L- ( PIPERIDIN-4-YL) -PYRAZOLE DERIVATIVES AS GPR 119 MODULATORS | PFIZER INC. (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110020460-A1 | GPR 119 MODULATORS | GPR119, GPR65, GPR88 | GPR119 1/4885JAK2 4200/4885JAK1 4365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.